Abstract
Cystatin C (CysC), a cysteine protease inhibitor, has been widely proven to be a highly sensitive biomarker to predict the kidney function. The similarity of the renal and cerebral small vessels has awakened a surge of studies suggesting that CysC plays a key role in various cerebrovascular disorders. This review focuses on four major mechanisms of CysC in a variety of cerebrovascular diseases. (1) The property of the CysC Leu-68-Gln (L68Q) variant to aggregate and the property of the wild type CysC protein to co-aggregate with Amyloid-β (Aβ); (2) The disruption of equilibrium between CysC and related cysteine proteases; (3) The function of CysC as an inflammatory inducing factor; (4) The ability of CysC to induce autophagy. The combination of these CysC properties provides a well-supported novel biomarker for cerebrovascular diseases.
Keywords: CysC, cerebrovascular diseases, cerebral amyloid angiopathy (CAA), cerebral aneurysms (CAs), subarachnoid hemorrhage (SAH), ischemic stroke, cerebral small vascular diseases (CSVDs), vascular dementia (VD).
Current Neurovascular Research
Title:Cystatin C in Cerebrovascular Disorders
Volume: 14 Issue: 4
Author(s): Yaru Zhang and Li Sun*
Affiliation:
- Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun,China
Keywords: CysC, cerebrovascular diseases, cerebral amyloid angiopathy (CAA), cerebral aneurysms (CAs), subarachnoid hemorrhage (SAH), ischemic stroke, cerebral small vascular diseases (CSVDs), vascular dementia (VD).
Abstract: Cystatin C (CysC), a cysteine protease inhibitor, has been widely proven to be a highly sensitive biomarker to predict the kidney function. The similarity of the renal and cerebral small vessels has awakened a surge of studies suggesting that CysC plays a key role in various cerebrovascular disorders. This review focuses on four major mechanisms of CysC in a variety of cerebrovascular diseases. (1) The property of the CysC Leu-68-Gln (L68Q) variant to aggregate and the property of the wild type CysC protein to co-aggregate with Amyloid-β (Aβ); (2) The disruption of equilibrium between CysC and related cysteine proteases; (3) The function of CysC as an inflammatory inducing factor; (4) The ability of CysC to induce autophagy. The combination of these CysC properties provides a well-supported novel biomarker for cerebrovascular diseases.
Export Options
About this article
Cite this article as:
Zhang Yaru and Sun Li *, Cystatin C in Cerebrovascular Disorders, Current Neurovascular Research 2017; 14 (4) . https://dx.doi.org/10.2174/1567202614666171116102504
DOI https://dx.doi.org/10.2174/1567202614666171116102504 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effects of Bisphosphonates and Calcium plus Vitamin-D Supplements on Cognitive Function in Postmenopausal Osteoporosis§
Endocrine, Metabolic & Immune Disorders - Drug Targets The Diagnostic Value of CSF Amyloid-β<sub>43</sub> in Differentiation of Dementia Syndromes
Current Alzheimer Research Phytochemical Therapies in Vascular Functioning: A Molecular Approach
Current Vascular Pharmacology β3-Adrenergic Receptors: Really Relevant Targets for Anti-Obesity Drugs?
Current Medicinal Chemistry - Central Nervous System Agents Therapeutic Approaches for Lysosomal Storage Diseases: A Patent Update
Recent Patents on CNS Drug Discovery (Discontinued) Targeting Heme Oxygenase-1 for Neuroprotection and Neuroinflammation in Neurodegenerative Diseases
Current Drug Targets Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews Platelets in Rheumatic Diseases: Friend or Foe?
Current Pharmaceutical Design Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward
Current Alzheimer Research Prostacyclin, Atherothrombosis and Diabetes Mellitus: Physiologic and Clinical Considerations
Current Molecular Medicine Regional Cerebral Blood Flow and Cerebrovascular Reactivity in Alzheimer’s Disease and Vascular Dementia Assessed by Arterial Spinlabeling Magnetic Resonance Imaging
Current Neurovascular Research Activation of Brain Endothelium by Soluble Aggregates of the Amyloid-β Protein Involves Nuclear Factor-κB
Current Alzheimer Research Beyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive Review
Current Neuropharmacology Inhibition of Early Biochemical Defects in Prodromal Huntington’s disease by Simultaneous Activation of Nrf2 and Elevation of Multiple Micronutrients
Current Aging Science Cellular Membrane Microparticles: Potential Targets of Combinational Therapy for Vascular Disease
Current Vascular Pharmacology FDG-PET in the Evaluation of Brain Metabolic Changes Induced by Cognitive Stimulation in aMCI Subjects
Current Radiopharmaceuticals Elevated Aβ42 in Aged, Non-demented Individuals with Cerebral Atherosclerosis
Current Alzheimer Research Renin-Angiotensin System: Role in Cerebrovascular, Neurodegenerative and Psychiatric Disease
Protein & Peptide Letters Vitamin D and Cardiovascular Disease
Current Vascular Pharmacology